Tiziana life sciences to present recent clinical updates at bio-europe in munich, germany, november 6-8, 2023

New york, nov. 01, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its chief operating officer and chief medical officer, matthew davis, md, rph, will present at bio-europe, munich, germany, november 6-8, 2023. the presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully human anti-cd3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as alzheimer's. tiziana's management will also be participating in one-on-one partnering meetings throughout the conference.
TLSA Ratings Summary
TLSA Quant Ranking